Massachusetts is currently home to 3366 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne
NCT06316297
Recruiting
The purpose of the trial is to evaluate the safety, efficacy and immunogenicity of one or two intramuscular injections of the Acne mRNA vaccine candidate at three dose levels in adult participants aged 18 to 45 years with moderate to severe acne in the US.
Gender:
All
Ages:
Between 18 years and 45 years
Trial Updated:
04/25/2024
Locations: Metro Boston Clinical Partners Site Number : 8400008, Brighton, Massachusetts
Conditions: Acne
Register for Updates
Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
NCT06302621
Recruiting
This study is researching whether the combination of Afatinib and Pemigatinib is safe and effective in FGFR altered unresectable or metastatic advanced solid tumors. The study is also trying to discover the highest doses of the study drugs that can be administered without causing any intolerable side effects. This research study involves the study drugs Afatinib and Pemigatinib.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Cholangiocarcinoma
Register for Updates
A Study of Second Look Laparoscopy (SLL) in People With Ovarian Cancer Who Have Completed Their First Course of Chemotherapy
NCT06240598
Recruiting
The researchers are doing this study to look at the health outcomes of people with advanced ovarian cancer who have a second look laparoscopy (SLL) after they complete their first course of chemotherapy. The researchers will compare the health outcomes of people who have minimal residual disease (MRD-small amounts of cancer cells in the body after a person receives treatment) at the time of SLL with the health outcomes of people who do not have MRD at the time of SLL. The researchers are also do... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey
Conditions: Ovarian Cancer
Register for Updates
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06212999
Recruiting
The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 [NCT05620823] or INCB 54707-302 [NCT05620836]).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Investigative Site US225, Boston, Massachusetts
Conditions: Hidradenitis Suppurativa (HS)
Register for Updates
Multicenter Symphony IL-6 Monitoring Sepsis ICU Study
NCT06181604
Recruiting
The primary objective of this study is to establish an IL-6 concentration cutoff and optimal time point(s) for using Symphony IL-6 that predict 28-day mortality in patients who are admitted or are intended to be admitted to the intensive care unit (ICU) diagnosed with sepsis or septic shock.
Gender:
All
Ages:
22 years and above
Trial Updated:
04/25/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Sepsis, Septic Shock
Register for Updates
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
NCT06179160
Recruiting
This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Solid Tumors
Register for Updates
TrinetX Study of Hypereosinophilic Syndrome (HES) Without an Identifiable Non-haematological Secondary Cause
NCT06172751
Recruiting
The purpose of this study is to build the knowledge base on clinical characteristics, clinical management, and treatment outcomes of HES.
Gender:
All
Ages:
All
Trial Updated:
04/25/2024
Locations: Research Site, Cambridge, Massachusetts
Conditions: Hypereosinophilic Syndrome (HES)
Register for Updates
AMX0035 and Progressive Supranuclear Palsy
NCT06122662
Recruiting
ORION Trial is a trial to evaluate the efficacy and safety of AMX0035 in participants with Progressive Supranuclear Palsy (PSP), consisting of a randomized double blind placebo controlled phase, followed by an optional open-label extension phase.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
04/25/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
Register for Updates
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06121843
Recruiting
The purpose of this study is to establish a safe and tolerable dose of BMS-986393 in combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed and/or refractory multiple myeloma (RRMM).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Multiple Myeloma
Register for Updates
A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C
NCT06119581
Recruiting
The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Boston Medical Center, Boston, Massachusetts
Conditions: Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Register for Updates
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
NCT06113445
Recruiting
This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Allcutis Research Inc Beverly, Beverly, Massachusetts
Conditions: NonSegmental Vitiligo
Register for Updates
Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa
NCT06079372
Recruiting
The primary purpose of this study is to assess the safety and tolerability of ALXN1850 versus asfotase alfa in pediatric participants with HPP previously treated with asfotase alfa.
Gender:
All
Ages:
Between 2 years and 11 years
Trial Updated:
04/25/2024
Locations: Research Site, Boston, Massachusetts
Conditions: Hypophosphatasia
Register for Updates